-
Science & technology
Science & technology
Novavax creates transformational vaccines that help address some of the world’s most pressing infectious diseases.
- Overview
- Our pipeline
- Matrix-M™ adjuvant
- Recombinant, protein-based nanoparticle vaccine
- Global vaccine approval/authorization map
COVID-19 UPDATESNovavax has demonstrated its ability to quickly produce viable vaccine candidates for emerging infectious diseases such as COVID-19.
-
Who we are
Who we are
We are a biotechnology company committed to help address serious infectious disease globally through the discovery, development, and delivery of innovative vaccines to patients around the world.
Build your future with usJoin other passionately curious people who are bringing innovative vaccines to the world
-
Insights
Insights
Novavax is committed to accelerating the development of new and promising vaccines by building on years of study and experience.
Insights
Explore our library of ever-evolving insightful articles from experienced thought leaders on vaccines and addressing public health threats.
Misinformation and misunderstandings: Five of the most common vaccine myths
November 2022
The case for COVID-19 vaccines for children
August 2022
Antibodies and immunity: Does vaccine protection last?
August 2022
An old, new foe: The global rise in vaccine-preventable diseases
August 2022
Statement on Novavax commitment to equitable access and transparency
March 2022
Diversity matters: Inclusivity in clinical trials
February 2022